References
- Gambacorti-Passerini C, Antolini L, Mahon FX, . Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 2011;103:553–561.
- Mahon FX, Rea D, Guilhot J, . Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010;11: 1029–1035.
- Duman BB, Paydas S, Disel U, . Secondary malignancy after imanitib therapy: eight cases and review of the literature. Leuk Lymphoma 2012;53:1706–1708.
- Ishibe N, Curtis RE. New malignancies following leukemia. In: Curtis RE, Freedman DM, Ron E, ., editors. New malignancies among cancer survivors: SEER cancer registries, 1973–2000. Bethesda, MD: National Cancer Institute; 2006. pp 437–464.
- Rebora P, Czene K, Antolini L, . Are chronic myeloid leukemia patients more at risk for second malignancies? A population-based study. Am J Epidemiol 2010;172:1028–1033.
- Rizzo JD, Curtis RE, Socie G, . Solid cancers after allogeneic hematopoietic cell transplantation. Blood 2009;113:1175–1183.
- Majhail NS, Brazauskas R, Rizzo JD, . Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. Blood 2011;117:316–322.
- Roy L, Guilhot J, Martineau G, . Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia. Leukemia 2005;19:1689–1692.
- Pilot PR, Sablinska K, Owen S, . Epidemiological analysis of second primary malignancies in more than 9500 patients treated with imatinib. Leukemia 2006;20:148; author reply 149.
- Verma D, Kantarjian H, Strom SS, . Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. Blood 2011;118:4353–4358.